Every 8-K that Merck & Co., Inc. (MRK) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow MRK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MRK filings page.
Merck & Co., Inc. reported second-quarter 2026 sales of $16,607 million, up 5% from $15,806 million, with Pharmaceutical sales of $14,760 million and Animal Health sales of $1,775 million, both up 5% and 8%, respectively. Growth was led by oncology and cardiometabolic products, including KEYTRUDA/KEYTRUDA QLEX at $8,366 million and WINREVAIR at $588 million, up 75%.
The company recorded a GAAP net loss of $1,335 million (EPS $(0.54)) and a non-GAAP net loss of $330 million (EPS $(0.13)), versus GAAP EPS of $1.76 and non-GAAP EPS of $2.13 a year earlier. Results were driven by a $5.7 billion R&D charge for the acquisition of Terns Pharmaceuticals, equal to $2.31 per share, which also pushed non-GAAP R&D to $9.7 billion.
Merck highlighted major regulatory milestones, including FDA approval of LIPFENDRA, multiple new KEYTRUDA-based regimens, and additional vaccine indications. For full-year 2026, it raised sales guidance to $66.3–$67.3 billion but cut non-GAAP EPS guidance to $2.66–$2.76 from $5.04–$5.16, reflecting one-time acquisition charges of $9.0 billion for Cidara and $5.7 billion for Terns.
Merck & Co., Inc. reported the results of shareholder voting from its Annual Meeting of Shareholders held on May 26, 2026. The report focuses on the submission of matters to a vote of security holders.
Shareholders cast detailed votes for the election of 13 directors, with each nominee receiving over 1.6 billion votes "For" and significant broker non-votes of 283,983,197 reported for each director. The company states that a majority of the votes cast was required for all six proposals presented at the meeting.
Merck & Co., Inc. closed an underwritten public offering of several series of senior notes. The company issued $500,000,000 of Floating Rate Notes due 2028, $1,000,000,000 of 4.300% Notes due 2028, and $500,000,000 of 4.650% Notes due 2031.
Merck also issued $1,000,000,000 of 4.950% Notes due 2033, $1,500,000,000 of 5.200% Notes due 2036, $500,000,000 of 5.750% Notes due 2046, and $1,000,000,000 of 5.850% Notes due 2056 under an existing shelf registration and a 2010 indenture.
Merck & Co., Inc. reported a first-quarter 2026 net loss driven by a large acquisition charge, despite solid sales growth. Sales were $16.286 billion, up 5% from $15.529 billion, led by oncology products such as KEYTRUDA, which generated $8.034 billion, up 12%, and strong 13% growth in Animal Health.
GAAP net loss attributable to Merck was $4.240 billion, or a loss of $1.72 per diluted share, versus earnings of $2.01 per share a year earlier. Non-GAAP loss per share was $1.28, compared with non-GAAP earnings of $2.22. Both GAAP and non-GAAP results were heavily affected by a $9.0 billion charge, equal to $3.62 per share, for the acquisition of Cidara Therapeutics.
Vaccines and diabetes franchises faced headwinds, with GARDASIL/GARDASIL 9 sales down 19% to $1.069 billion and JANUVIA/JANUMET down 28% to $574 million. Merck updated its 2026 outlook to forecast sales of $65.8 billion to $67.0 billion and non-GAAP EPS of $5.04 to $5.16, including the Cidara charge. A separate tender offer to acquire Terns is expected to be accounted for as an asset acquisition, resulting in an additional one-time charge of approximately $5.8 billion, or about $2.35 per share, plus an estimated $0.12 EPS impact over the remainder of 2026 after closing.
Merck & Co., Inc. filed a Form 8-K to furnish information about its earnings for the fourth quarter and full year 2025. The filing references a February 3, 2026 press release attached as Exhibit 99.1 and additional supplemental information attached as Exhibit 99.2.
The company states this earnings information is being furnished under Item 2.02, not filed for liability purposes under the Exchange Act, and will only be incorporated into other filings if specifically referenced.
Merck & Co., Inc. reported that on December 4, 2025 it closed an underwritten public offering of multiple series of senior notes under its automatic shelf registration. The offering includes $500,000,000 aggregate principal amount of Floating Rate Notes due 2029, $750,000,000 of 3.850% Notes due 2029, $1,000,000,000 of 4.150% Notes due 2031 and $1,000,000,000 of 4.450% Notes due 2032.
Merck also issued $1,500,000,000 of 4.750% Notes due 2035, $750,000,000 of 5.500% Notes due 2046, $1,500,000,000 of 5.550% Notes due 2055 and $1,000,000,000 of 5.700% Notes due 2065. The notes were issued under an existing indenture dated January 6, 2010 with U.S. Bank Trust National Association as trustee, and related officers’ certificates and a legal opinion were filed as exhibits.
Merck & Co., Inc. (MRK) furnished an 8-K under Item 2.02, providing an earnings press release for the third quarter of 2025 as Exhibit 99.1 and additional supplemental materials as Exhibit 99.2. The company states this information is being furnished and is not deemed filed under Section 18 of the Exchange Act.
The filing also includes Exhibit 104 (Cover Page Interactive Data File). Merck’s common stock trades on the NYSE under MRK.
Merck & Co., Inc. completed an underwritten public offering of new investment-grade debt across multiple maturities. The company issued $500,000,000 of Floating Rate Notes due 2027, $750,000,000 of 3.850% Notes due 2027, $750,000,000 of 4.150% Notes due 2030, $1,000,000,000 of 4.550% Notes due 2032, $1,750,000,000 of 4.950% Notes due 2035, and $1,250,000,000 of 5.700% Notes due 2055 under an existing shelf registration. All notes were issued under Merck’s longstanding indenture with U.S. Bank Trust National Association, and the filing also attaches officers’ certificates and a legal opinion related to the new series.
Merck & Co., Inc. (NYSE: MRK) filed an 8-K disclosing two key items. Item 2.02 furnishes, but does not file, the company’s Q2-25 earnings press release (Ex. 99.1) and related supplemental information (Ex. 99.2); specific financial figures are not included in this filing.
Item 2.05 launches a new “2025 Restructuring Program.” Approved 25 Jul 2025, the plan targets sales, administrative and R&D head-count reductions, a smaller real-estate footprint and continued manufacturing network optimization. Merck expects:
- Total pretax charges: ≈ $3.0 billion; ~60 % cash (severance & contract terminations) and the balance non-cash (accelerated depreciation).
- Major actions largely finished by end-2027; manufacturing actions substantially done by end-2029.
- Annual cost savings: ≈ $1.7 billion realized by end-2027.